Latest Casdin Capital, LLC Stock Portfolio
Casdin Capital, LLC Performance:
2024 Q3: 9.18%YTD: 21.28%2023: -13.17%
Performance for 2024 Q3 is 9.18%, and YTD is 21.28%, and 2023 is -13.17%.
About Casdin Capital, LLC and 13F Hedge Fund Stock Holdings
Casdin Capital, LLC is a hedge fund based in NEW YORK, NY. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $2.7 Billions. In it's latest 13F Holdings report, Casdin Capital, LLC reported an equity portfolio of $1.5 Billions as of 30 Sep, 2024.
The top stock holdings of Casdin Capital, LLC are BLFS, RVMD, SMFR. The fund has invested 14.5% of it's portfolio in BIOLIFE SOLUTIONS INC and 12.4% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off PLIANT THERAPEUTICS INC (PLRX), KYVERNA THERAPEUTICS INC and GINKGO BIOWORKS HOLDINGS INC (DNA) stocks. They significantly reduced their stock positions in MONTE ROSA THERAPEUTICS INC (GLUE), CENTURY THERAPEUTICS INC (IPSC) and DENALI THERAPEUTICS INC (DNLI). Casdin Capital, LLC opened new stock positions in GINKGO BIOWORKS HOLDINGS INC (DNA). The fund showed a lot of confidence in some stocks as they added substantially to GRAIL INC, CODEXIS INC (CDXS) and GUARDANT HEALTH INC (GH).
The top stock holdings of Casdin Capital, LLC are BLFS, RVMD, SMFR. The fund has invested 14.5% of it's portfolio in BIOLIFE SOLUTIONS INC and 12.4% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off PLIANT THERAPEUTICS INC (PLRX), KYVERNA THERAPEUTICS INC and GINKGO BIOWORKS HOLDINGS INC (DNA) stocks. They significantly reduced their stock positions in MONTE ROSA THERAPEUTICS INC (GLUE), CENTURY THERAPEUTICS INC (IPSC) and DENALI THERAPEUTICS INC (DNLI). Casdin Capital, LLC opened new stock positions in GINKGO BIOWORKS HOLDINGS INC (DNA). The fund showed a lot of confidence in some stocks as they added substantially to GRAIL INC, CODEXIS INC (CDXS) and GUARDANT HEALTH INC (GH).
Casdin Capital, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Casdin Capital, LLC made a return of 9.18% in the last quarter. In trailing 12 months, it's portfolio return was 32.14%.
New Buys
| Ticker | $ Bought |
|---|---|
| ginkgo bioworks holdings inc | 297,418 |
New stocks bought by Casdin Capital, LLC
Additions
| Ticker | % Inc. |
|---|---|
| grail inc | 337 |
| codexis inc | 305 |
| guardant health inc | 250 |
| syndax pharmaceuticals inc | 216 |
| illumina inc | 56.25 |
| 4d molecular therapeutics in | 43.75 |
| verve therapeutics inc | 30.61 |
| beam therapeutics inc | 14.81 |
Additions to existing portfolio by Casdin Capital, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| monte rosa therapeutics inc | -67.05 |
| century therapeutics inc | -38.11 |
| denali therapeutics inc | -23.85 |
| veracyte inc | -22.33 |
| revolution medicines inc | -6.64 |
| genedx holdings corp | -0.55 |
Casdin Capital, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| pliant therapeutics inc | -10,750,000 |
| kyverna therapeutics inc | -4,312,500 |
| singular genomics systems in | -372,890 |
| ginkgo bioworks holdings inc | -487,993 |
Casdin Capital, LLC got rid off the above stocks
Sector Distribution
Casdin Capital, LLC has about 85.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 85.7 |
| 9.9 | |
| Others | 4.4 |
Market Cap. Distribution
Casdin Capital, LLC has about 21.5% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 43.2 |
| MID-CAP | 27.3 |
| LARGE-CAP | 21.5 |
| UNALLOCATED | 4.4 |
| MICRO-CAP | 3.6 |
Stocks belong to which Index?
About 61.2% of the stocks held by Casdin Capital, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 54.7 |
| Others | 38.8 |
| S&P 500 | 6.5 |
Casdin Capital, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Casdin Capital, LLC
Casdin Capital, LLC has 35 stocks in it's portfolio. About 78.3% of the portfolio is in top 10 stocks. SRPT proved to be the most loss making stock for the portfolio. SMFR was the most profitable stock for Casdin Capital, LLC last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABSI | absci corporation | 0.25 | 973,260 | 3,717,850 | unchanged | 0.00 | ||
| ALNY | alnylam pharmaceuticals inc | 3.12 | 170,000 | 46,755,100 | unchanged | 0.00 | ||
| BEAM | beam therapeutics inc | 1.27 | 775,000 | 18,987,500 | added | 14.81 | ||
| BLFS | biolife solutions inc | 14.54 | 8,707,160 | 218,027,000 | unchanged | 0.00 | ||
| BPMC | blueprint medicines corp | 2.01 | 326,378 | 30,190,000 | unchanged | 0.00 | ||
| CDXS | codexis inc | 1.66 | 8,100,000 | 24,948,000 | added | 305 | ||
| DNA | ginkgo bioworks holdings inc | 0.02 | 36,493 | 297,418 | new | |||
| DNA | ginkgo bioworks holdings inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DNLI | denali therapeutics inc | 1.92 | 990,000 | 28,838,700 | reduced | -23.85 | ||
| EXAS | exact sciences corp | 2.95 | 650,000 | 44,278,000 | unchanged | 0.00 | ||
| FDMT | 4d molecular therapeutics in | 0.83 | 1,150,000 | 12,431,500 | added | 43.75 | ||
| GH | guardant health inc | 0.54 | 350,000 | 8,029,000 | added | 250 | ||
| GLUE | monte rosa therapeutics inc | 0.03 | 86,014 | 455,874 | reduced | -67.05 | ||
| ILMN | illumina inc | 6.52 | 750,000 | 97,807,500 | added | 56.25 | ||
| IPSC | century therapeutics inc | 0.37 | 3,212,320 | 5,493,060 | reduced | -38.11 | ||
| KRON | kronos bio inc | 0.01 | 123,839 | 123,827 | unchanged | 0.00 | ||
| LAB | standard biotools inc | 9.17 | 71,254,700 | 137,522,000 | added | 11.41 | ||
| NTLA | intellia therapeutics inc | 2.74 | 2,000,000 | 41,100,000 | unchanged | 0.00 | ||
| OMIC | singular genomics systems in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PACB | pacific biosciences calif in | 0.12 | 1,035,860 | 1,760,960 | unchanged | 0.00 | ||